154 related articles for article (PubMed ID: 18701180)
1. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
Roedl JB; Colen RR; Holalkere NS; Fischman AJ; Choi NC; Blake MA
Radiother Oncol; 2008 Dec; 89(3):278-86. PubMed ID: 18701180
[TBL] [Abstract][Full Text] [Related]
2. Roedl JB et al., Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT comparison to histopathologic and clinical response evaluation, Radiother Oncol 2008; 89: 278-86.
Fleming CE; Bass G; Walsh TN
Radiother Oncol; 2009 Aug; 92(2):291. PubMed ID: 19264369
[No Abstract] [Full Text] [Related]
3. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA; Eloubeidi MA
J Thorac Cardiovasc Surg; 2005 Jun; 129(6):1232-41. PubMed ID: 15942562
[TBL] [Abstract][Full Text] [Related]
4. Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy.
Bruzzi JF; Swisher SG; Truong MT; Munden RF; Hofstetter WL; Macapinlac HA; Correa AM; Mawlawi O; Ajani JA; Komaki RR; Fukami N; Erasmus JJ
Cancer; 2007 Jan; 109(1):125-34. PubMed ID: 17146785
[TBL] [Abstract][Full Text] [Related]
5. Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET.
Sloof GW
Best Pract Res Clin Gastroenterol; 2006; 20(5):941-57. PubMed ID: 16997171
[TBL] [Abstract][Full Text] [Related]
6. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
[TBL] [Abstract][Full Text] [Related]
7. Tumor volume assessment by 18F-FDG PET/CT in patients with oral cavity cancer with dental artifacts on CT or MR images.
Baek CH; Chung MK; Son YI; Choi JY; Kim HJ; Yim YJ; Ko YH; Choi J; Cho JK; Jeong HS
J Nucl Med; 2008 Sep; 49(9):1422-8. PubMed ID: 18703597
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
9. Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography.
Roedl JB; Harisinghani MG; Colen RR; Fischman AJ; Blake MA; Mathisen DJ; Mueller PR
Ann Thorac Surg; 2008 Oct; 86(4):1131-8. PubMed ID: 18805147
[TBL] [Abstract][Full Text] [Related]
10. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
[TBL] [Abstract][Full Text] [Related]
11. Role of Repeat 18F-Fluorodeoxyglucose Positron Emission Tomography Examination in Predicting Pathologic Response Following Neoadjuvant Chemoradiotherapy for Esophageal Adenocarcinoma.
Kukar M; Alnaji RM; Jabi F; Platz TA; Attwood K; Nava H; Ben-David K; Mattson D; Salerno K; Malhotra U; Kanehira K; Gannon J; Hochwald SN
JAMA Surg; 2015 Jun; 150(6):555-62. PubMed ID: 25902198
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
13. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
Ceresoli GL; Chiti A; Zucali PA; Rodari M; Lutman RF; Salamina S; Incarbone M; Alloisio M; Santoro A
J Clin Oncol; 2006 Oct; 24(28):4587-93. PubMed ID: 17008700
[TBL] [Abstract][Full Text] [Related]
14. Volumetric parameters of 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography/computed tomography can predict histopathologic treatment response after neoadjuvant chemoradiotherapy in pancreatic adenocarcinoma.
Sakane M; Tatsumi M; Hori M; Onishi H; Tsuboyama T; Nakamoto A; Ota T; Eguchi H; Wakasa K; Hatazawa J; Tomiyama N
Eur J Radiol; 2017 Sep; 94():64-69. PubMed ID: 28712692
[TBL] [Abstract][Full Text] [Related]
15. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
[TBL] [Abstract][Full Text] [Related]
17. Intratreatment Response Assessment With 18F-FDG PET: Correlation of Semiquantitative PET Features With Pathologic Response of Esophageal Cancer to Neoadjuvant Chemoradiotherapy.
Tandberg DJ; Cui Y; Rushing CN; Hong JC; Ackerson BG; Marin D; Zhang X; Czito BG; Willett CW; Palta M
Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1002-1007. PubMed ID: 30055238
[TBL] [Abstract][Full Text] [Related]
18. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.
Lastoria S; Piccirillo MC; Caracò C; Nasti G; Aloj L; Arrichiello C; de Lutio di Castelguidone E; Tatangelo F; Ottaiano A; Iaffaioli RV; Izzo F; Romano G; Giordano P; Signoriello S; Gallo C; Perrone F
J Nucl Med; 2013 Dec; 54(12):2062-9. PubMed ID: 24136935
[TBL] [Abstract][Full Text] [Related]
19. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.
Roedl JB; Halpern EF; Colen RR; Sahani DV; Fischman AJ; Blake MA
Mol Imaging Biol; 2009; 11(1):54-60. PubMed ID: 18769974
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 18F-FDG positron emission tomography and computed tomography in patients with colorectal carcinoma and lymphoma: our initial clinical experience.
Coha B; Radmilović K; Gardasanić J; Daković M; Stefanić M; Latić A; Mitrecić D
Acta Clin Croat; 2009 Mar; 48(1):35-9. PubMed ID: 19623870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]